Skip to content
Back to meeting Original
Julien Mazieres· @JulienMazieres · X·· 17 hours agoScore70
Body

Divarasib significantly improved PFS (9.8 vs 5.7 m) and OS (12 vs 17.7) vs control (soto or ada) with a manageable safety profile (GI toxicity) in previously treated advanced/metastatic KRAS G12C-mutated NSCLC. @myESMO @OncoAlert proud to be part of it. @CHUdeToulouse #ESMO26

69 views · 2 likes · 2 reposts · 0 replies

Source: Julien Mazieres · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.